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Abstract
The transcription factor Pit-1/Pou1f1 regulates GH and prolactin (PRL) secretion in the pituitary
gland. Pit-1 expression and GH regulation by Pit-1 have also been demonstrated in mammary
gland. However, no data are available on the role of Pit-1 on breast PRL. To evaluate this role,
several human breast cancercell lines were transfectedwith either the Pit-1 expression vectoror a
Pit-1 small interference RNA construct, followed by PRL mRNA and protein evaluation. In
addition, transient transfection of MCF-7 cells by a reporter construct containing the proximal PRL
promoter, and ChIP assays were performed. Our data indicate that Pit-1 regulates mammary PRL
at transcriptional level by binding to the proximal PRL promoter. We also found that Pit-1 raises
cyclin D1 expression before increasing PRL levels, suggesting a PRL-independent effect of Pit-1
on cell proliferation. By using immunohistochemistry, we found a signiﬁcant correlation between
Pit-1 and PRL expression in 94 human breast invasive ductal carcinomas. Considering the
possible role of PRL in breast cancer disorders, the function of Pit-1 in breast should be the focus
of further research.
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Introduction
The transcription factor Pit-1/Pou1f1 was ﬁrst
described in the pituitary gland, where it acts in cell
differentiation during organogenesis of the anterior
pituitary in mammals and as a transcriptional activator
for pituitary gene transcription (Lefevre et al. 1987,
Nelson et al. 1988). Mice with inactivating mutations
or deletions of the Pit-1 gene fail to generate
somatotrophs, lactotrophs, and thyrotrophs, and
consequently exhibit anterior pituitary hypoplasia
and dwarﬁsm (Li et al. 1990), thereby demonstrating
the importance of Pit-1 in the ontogeny of the
pituitary gland. While its pituitary function has been
extensively evaluated, Pit-1 is also expressed in
several extrapituitary tissues and cell lines, including
the mammary gland, where its role is still unclear
(Delhase et al.1 9 9 3 , Bamberger et al. 1995,
Gil-Puig et al.2 0 0 2 , 2005). Moreover, as in the
pituitary gland, Pit-1 regulates GH expression in
the MCF-7 human breast adenocarcinoma cell line
(Gil-Puig et al. 2005).
Prolactin (PRL) and its corresponding receptor
have also been found in extrapituitary tissues,
including normal human breast, mammary tumors,
and breast cell lines (Clevenger et al. 1995, Ginsburg
& Vonderhaar 1995, Mertani et al. 1998), but the
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stood. Human PRL gene is regulated at a transcrip-
tional level by two different promoters (Berwaer et al.
1994, Gellersen et al. 1994). First, the proximal
pituitary promoter is located in the exon 1b and
contains Pit-1 response elements; the human pituitary
PRL gene contains only this promoter. Secondly, the
distal or extrapituitary promoter is located at 5.8 kb
upstream of the above mentioned proximal PRL
promoter and does not contain any Pit-1-binding
sites. The distal promoter is present in PRL gene at
extrapituitary sites, such as placenta, lymphoid cells,
normal and neoplastic human breast, and human
prostate (Berwaer et al. 1994, Gellersen et al. 1994,
Shaw-Bruha et al. 1997, Dagvadorj et al. 2007).
However, both proximal pituitary and distal extra-
pituitary PRL promoters are expressed in a subset of
normal and tumoral breast tissues, breast cell lines,
and in prostate tissue (Shaw-Bruha et al. 1997,
Dagvadorj et al. 2007). PRL transcripts arising from
either the distal or proximal promoter encode
identical proteins, which gives the PRL gene a
tissue-speciﬁc regulation. The effects of PRL on
milk production and on mammary growth and
differentiation are well known (Freeman et al.
2000). In addition, PRL provides a proliferative
stimulus to rodent mammary tumorogenesis (Welsch
& Nagasawa 1977). Several researchers have related
endocrine and/or autocrine/paracrine PRL production
with mammary disorders, including tumorogenesis
(Vonderhaar 1999, Wennbo & To ¨rnell 2000, Ben-
Jonathan et al.2 0 0 2 , Clevenger et al. 2003). For
instance, recent prospective studies have linked PRL
levels with breast cancer etiology in women,
particularly in estrogen-positive tumors (Tworoger
et al. 2007). The administration of anti-PRL
antibodies, PRL antisense oligonucleotides, or PRL
antagonists suppresses the mitogenic activity of
locally produced PRL and inhibits growth in breast
tumor cell lines (Fuh & Wells 1995, Llovera et al.
2000). In addition, transgenic mice that overexpress
the PRL gene develop mammary carcinoma, and this
tumor development is caused by the activation of
PRL receptor (Wennbo et al. 1997).
To explore the regulation of autocrine breast PRL,
in the present study, several human breast cell lines
were used to evaluate the effect of Pit-1 over-
expression and/or knockdown on PRL expression.
In addition, we evaluate the effect of Pit-1 and PRL
on cell proliferation. Finally, we evaluate the
relationships between Pit-1 and PRL expression in
human breast tumors.
Materials and methods
Cell culture
Human breast carcinoma cell lines (MCF-7, SK-BR-3,
MDA-MB-231, BT474, and T47D), NIH-3T3 (mouse
embryonic ﬁbroblast), and HeLa (human cervix
carcinoma) cells lines were grown in 90-mm petri
dishes in DMEM supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 mg/ml strepto-
mycin, and 2 mM L-glutamine in an air–CO2 (95:5)
atmosphere at 37 8C. Conﬂuent cells were washed
twice with PBS and harvested by a brief incubation
with trypsin–EDTA solution (Sigma–Aldrich) in PBS.
Plasmids, transfections, site-directed
mutagenesis, and treatments
Cells were cultured as described above. Twelve to
24 h before transfection, 10
6 or 2!10
5 cells/well
were seeded in 90-mm petri dishes or 6-well plates
respectively and allowed to attach overnight. To
evaluate PRL and Pit-1 mRNA and protein
expression after Pit-1 overexpression or after Pit-1
knockdown, cells were a) transfected with 4 mgo f
pRSV-hPit-1 expression construct (obtained from
Dr J L Castrillo) or with 4 mg of pRc/RSV empty
vector (employed as a control), using FuGene (Roche
Molecular Biochemicals); or b) transfected with
20 nM Pit-1 small interference RNA (siRNA) or
with 20 nM mis-sense siRNA (employed as a
control), using jetSI (jetSI siRNA transfection
reagent, Polyplus-Transfection, Illkirch, France) as
previously described (Seoane et al. 2007). Cells were
incubated for varying periods of time as indicated,
and total RNA isolation (for RT-PCR or real-time
PCR assays) and protein extraction (for western blot
assays) were then performed.
To evaluate PRL, Pit-1 and cyclin D1 protein
expression 48 h after both PRL knockdown and Pit-1
overexpression, MCF-7 cells were cotransfected using
jetSI-ENDO (Polyplus-Transfection) with two PRL
siRNAs, which hybridise to the PRL gene at 521 and
933 bp (20 nM, Sigma–Aldrich), and with 2.5 mg
pRSV-hPit-1 overexpression vector.
The proximal promoter region of the human PRL
gene (K216/C1; pGL2B-hPRLK216/C1) was synthe-
tized by PCR using the oligonucleotides: forward,
50-CCGCTCGAGCCTAATTAATCAAAATCCTTC-30;
and reverse, 50-AAGCTTTTCTCTTTCCCAGA-
TATTG-30. The PCR product was subcloned into the
XhoI and HindIII site of the pGL2-basic plasmid. In
addition, the pGL2B-hPRLK216/C1 vector was mutated
at two Pit-1 consensus binding sites, positioned
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and K108 and K106 bp (mut1) respectively from
the transcription start site on the hPRL gene.
Site-directed mutagenesis was performed with the
QuikChange kit (Stratagene, La Jolla, CA, USA) under
the conditions recommended by the manufacturer. The
mutagenised oligonucleotide primers were as follows
(mutagenised bases on the sense strand indicated
bylowercaseletters):50-ATGTCTTCCTGAATATGcc-
cAAAGAAATAAA-30 and 50-TTGAAATTAT-
GGGGGTcccCTCAATGACGG-30 (designated mut2
and mut1 respectively). Subsequently, a double mutant
was constructed using the same method (designated
pGL2B-hPRLmut1C2). All the nucleotide sequences of
the cloned inserts were conﬁrmed by sequencing.
Transfections were carried out in wells containing
1 ml Fugene (Roche Molecular Biochemicals) and
1 mg total DNA (750 ng pGL2-basic vector,
pGL2B-hPRLK216/C1,p G L 2 B - h P R L mut2,p G L 2 B -
hPRLmut1, or pGL2B-hPRLmut1C2 constructs, and
250 ng Rous sarcoma virus b-galactosidase (pRSV-
gal)). The cells were cotransfected with 1 mg Pit-1
(pRSV-hPit-1) or pRc–RSV empty vector (control
cells). Each experiment was performed in triplicate
cultures. The cells were harvested in buffer (5! lysis
buffer; Promega), and luciferase activity was then
measured. b-Galactosidase activity was measured at
420 nm using a using o-nitrophenyl-b-D-galactopyr-
anoside as substrate.
For PRL treatment, 24 h after transfection, MCF-7
cellswere treated with 10 nM humanPRL (hPRL,from
Dr Parlow, NIDDK, USA) for 24 h. MCF-7 cells were
also treated with AG-490 (a potent inhibitor of the
Jak2 tyrosine kinase; Calbiochem, San Diego, CA,
USA). AG-490 was dissolved in dimethyl sulfoxide
(DMSO)andusedat30 mMfor24 h.Aspositivecontrol
for Jak2 activation, we used H2O2 (500 mM) for 1 h.
RNA isolation, RT-PCR, and quantitative PCR
Isolation of total RNA from the cell lines was
performed with the TRIzol reagent (Invitrogen),
according to the manufacturer’s instructions. cDNA
synthesis was performed as described elsewhere
(Gil-Puig et al. 2005). Five microliters of the cDNA
were ampliﬁed by PCR using 2 units of Taq
polymerase (Gene Craft, Koln, Germany) in a buffer
containing 50 mM KCl, 10 mM Tris–HCl (pH 8.4),
and 1.5 mM MgCl2, with each dNTP at 0.2 mM and
each of twooligonucleotide primers at 25 pM, to a total
volume of 50 ml. The sample was denatured at 94 8C
for 1 min, annealed at 54, 58, or 60 8C for 1 min
(PRL, Pit-1, and 18S respectively) and extended at
72 8C for 1 min, for a total of 30, 32, or 36 cycles (for
18S, Pit-1, and PRL respectively) with an extension
step of 10 min at 72 8C in the ﬁnal cycle.
PRL and 18S mRNA levels from MCF-7, BT474,
SK-BR-3, T47D, and MDA-MB-231 cell lines were
quantiﬁed using real-time PCR. Reactions were done
using iQ SYBR Green Supermix (Bio-Rad) on iCycler
equipment (Bio-Rad). The samples (PRL and 18S)
were denatured at 94 8C for 10 s, annealed at 58 8C for
10 s, and extended at 72 8C for 10 s, for a total of 40
cycles. The samples were quantiﬁed using the Optical
System Software 2.0 (Bio-Rad), with 18S as normal-
ization control.
Primer sequences
Primer sequences for PRL PCR ampliﬁcation were as
follows: primer Ex1a (50-GAGACACCAAGAA-
GAATCGGAACATAC-30) was a 27-mer correspond-
ing to exon 1a of PRL cDNA; primer Ex1b
(50-AGACTTCCAGATCTTCTCTGGTGAAG-30)w a s
a 26-mer corresponding to exon 1b of PRL cDNA;
primer Ex2 (50-TCAAACAGGTCTCGAAGGGT-
CACCT-30) was an antisense 25-mer corresponding
to exon 2 of PRL cDNA; primer Ex4 (50-AGCAAAC-
CAAACGGCT-30) was a 16-mer corresponding to
exon 4 of PRL cDNA; and primer Ex5 (50-AGGCGA-
GACTCTTCAT-30) was an antisense 16-mer corre-
sponding to exon 5 of PRL cDNA. The lengths of the
PCRproductsobtainedwere275 bp(Ex1a–Ex2),194 bp
(Ex1b–Ex2), and 133 bp (Ex4–Ex5). For PRL, quan-
titativePCRevaluationswereusedtheEx4–Ex5primers.
Pit-1 primer sequences were as follows: forward primer,
50-GTGTCTACCAGTCTCCAACC-30; and reverse
primer, 50-ACTTTTCCGCCTGAGTTCCT-30.T h e
length of the product obtained was 247 bp. Human 18S
rRNA was used as internal reference. Primer sequences
were as follows: forward primer, 50-GTAACCCGTT-
GAACCCCATT-30; and reverse primer, 50-CCATC-
CAATCGCTA GTAGCG-30. The length of the PCR
product obtained was 131 bp.
Western blot analysis
Cells were lysed at 4 8C in 300 ml lysis buffer (50 mM
HEPES, pH 7.5; 150 mM NaCl; 5 mM EGTA; 1.5 mM
MgCl2; 1% SDS; 10% glycerol; 1% Triton X-100;
10 mM sodium orthovanadate; 4 mM phenylmethyl-
sulphonyl ﬂuoride (PMSF), and 50 mg/ml aprotinin).
The cell lysate was then centrifuged at 14 000 g for
5 min at 4 8C, the resulting supernatant was collected,
and protein concentration was determined by the
Bradford method. Western blotting of Pit-1 from
MCF-7 cells was carried out as described elsewhere
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protein were subjected to 12% (for Pit-1, cyclin D1,
and b-actin) or 15% (for PRL) SDS–PAGE electro-
phoresis. Proteins were transferred to a nitrocellulose
membrane that was blocked and washed. The blot was
immunolabeled overnight at 4 8C with a polyclonal
anti-Pit-1 antiserum (1:500, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), or with a polyclonal anti-PRL
antiserum (1:5000, from Dr Parlow, NIDDK), then
incubated with goat anti-rabbit IgG (1:5000, for Pit-1,
and PRL, see below) or with anti-mouse IgG (1:5000,
for cyclin D1 and b-actin) peroxidase-conjugated
second antibody, using the ECL western blotting
analysis system (GE Healthcare, Piscataway, NJ,
USA), and visualized by placing the blot in contact
with standard X-ray ﬁlm, as per the manufacturer’s
instructions. Membranes were stripped by incubation
in 0.2 M glycine, pH 2.2, containing 0.1% SDS and 1%
Tween 20 at room temperature for 1 h, and then
reprobed with a monoclonal anti-cyclin D1 antibody
(1:400, Santa Cruz Biotechnology) and monoclonal
anti-b-actin antiserum (1:2000, Sigma–Aldrich).
The optical density of immunolabeling on auto-
radiographic ﬁlm was quantiﬁed using the UN-SCAN-
IT program, version 6.1. To determine the relative
amounts of Pit-1, cyclin D1, PRL, and b-actin in each
sample, absolute amounts of Pit-1, cyclin D1, and PRL
were expressed relative to b-actin amounts.
ChIP assays
Chromatin immunoprecipitation (ChIP) assays were
performedusingtheprotocolofUpstate(Charlottesville,
VA, USA) as previously described (Seoane &
Perez-Fernandez 2006). Diluted soluble chromatin
fractions were immunoprecipitated with 1 mg poly-
clonal anti-Pit-1 antibody (Santa Cruz Biotechnology)
or control human IgG (Sigma–Aldrich). The histone-
DNA crosslinks were reversed by 4-h incubation at
65 8C. The DNA from these samples was extracted
through phenol/chloroform and ethanol precipitated
with 20 mg glycogen. The DNA extracted was then
dissolved in 30 mlH 2O. PCR was used to analyze the
DNA fragments from ChIP assays. Five microliters of
assayed DNA sample and 5 ml of input/start material
were used in each 50-ml reaction. The PCR was run for
60 s at 95, 60, and 72 8C within each cycle, for a total
of 35 cycles. The pairs of PRL primers were as follows:
(A) forward, 50-CCGCTCGAGCCTAATTAATCAAA-
ATCCTTC-30 and reverse, 50-CCCAAGCTTTTC-
TCTTTCCCAGATATTG-30; PCR product is 217 bp
in length (from K216 to C1 bp, with respect to the
start transcription site in the proximal PRL promoter).
Bromodeoxyuridine incorporation
MCF-7 cells (50!10
3 cells/well) were seeded in
24-well dishes with coverslides, and allowed to attach
overnight. To evaluate bromodeoxyuridine (BrdU)
incorporation after Pit-1 overexpression or after Pit-1
knockdown, cells were cotransfected using the pEPuro
construct (that confers puromycin resistance), and the
pRSV-hPit-1 construct (500 ng) or Pit-1 siRNA
(20 nM) respectively and selected (1 mg/ml of pur-
omycin). Forty-eight hours later, resistant cells were
labeled with 10 mM BrdU for 1 h. Cells were then ﬁxed
15 min in formaldehyde 4%, 5 min in PBS, and
overnight in methanol, permeabilized in 0.07 M
NaOH; and incubated overnight at 4 8C with 1:100
a-BrdU (BD Biosciences, San Diego, CA, USA),
followed by 1:150 F (ab) IgG FICT (Jackson
Immunoresearch, West Grove, PA, USA) plus 4,6-
diamino-2-phenylindone (DAPI) for 45 min at 37 8Ci n
darkness in a humidiﬁed chamber.
Breast cancer samples and
immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded breast tissue sec-
tions were obtained from 94 patients with histological
diagnosis of invasive ductal carcinoma of the breast,
which underwent surgery at Fundacio ´n Hospital de
Jove of Gijo ´n (Spain), between 1995 and 2006. The
tissue samples were obtained at the time of surgery.
Prior informed consent was obtained from patients.
The study adhered to National regulations and was
approved by our Institution’s Ethics and Investigation
Committee.
Serial 5-mm sections were consecutively cut with a
microtome (Leica Microsystems GmbH, Wetzlar,
Germany) and transferred to adhesive-coated slides.
Immunohistochemistry was done on these sections
using a TechMate TM50 autostainer (Dako, Glostrup,
Denmark). Antibodies for Pit-1 and PRL were
obtained from Santa Cruz Biotechnology and from
Dr Parlow respectively. We used human pituitary
gland (obtained from autopsy) as positive control for
both PRL and Pit-1.
Tissue sections were deparafﬁnized in xylene, and
then rehydrated in decreasing concentrations of ethanol
(100, 96, 80, 70%, then water). To enhance antigen
retrieval, sections were microwave treated (H2800
Microwave Processor, EBSciences, East Granby, CT,
USA) in citrate buffer (Target Retrieval Solution,
Dako) at 99 8C for 1 min. Endogenous peroxidase
activity was blocked by incubating the slides in
peroxidase-blocking solution (Dako) for 5 min. The
EnVision Detection Kit (Dako) was used as the
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stained with hematoxylin, dehydrated with ethanol,
and permanently coverslipped.
A case was considered as positive if at least 10%
of tumoral cells showed positive immunostaining.
In addition, as the intensity of staining varied among
tumors, positive cases were classiﬁed as weak (1C),
moderate (2C), and intense (3C) staining.
Statistical analysis
Each experiment was performed at least thrice. Values
are expressed as meansGS.D. Means were compared
by unpaired t-tests or one-way ANOVA with the
Tukey–Kramer multiple comparison test for post-hoc
comparisons. Differences in percentages in the
immunohistochemistry analyses were calculated with
the c
2 test. Statistical signiﬁcance is taken to be
indicated by P!0.05.
Results
Effect of Pit-1 overexpression and knockdown on
PRL levels
PCR ampliﬁcation of cDNA prepared from SK-BR-3,
MCF-7, MDA-MB-231, BT474, and T47D human
breast adenocarcinoma cells using primers Ex4 and
Ex5 yielded a 133-bp PCR product corresponding to
PRL (Fig. 1A). In order to evaluate PRL regulation
by Pit-1, pRSV-hPit-1 vector was transfected in each
cell line, and PRL mRNA was evaluated by both
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Figure 1 Pit-1 regulates PRL expression in human mammary cell lines. (A) PRL, Pit-1, and 18S mRNA before and after 48 h of Pit-1
overexpression in the SK-BR-3, MCF-7, MDA-MB-231, BT47, and T47D cell lines. (B) Real-time PCR of PRL mRNA expression,
with respect to 18S mRNA levels, evaluated in control and pRSV-hPit-1-transfected SK-BR-3, MCF-7, MDA-MB-231, BT47, and
T47D cell lines. (C) MCF-7 cells were transfected with either empty pRc/RSV vector (control, C) or pRSV-hPit-1 construct at 24, 48,
and 72 h respectively. Values represent meansGS.D. from four independent determinations. (D) Western blots of Pit-1, PRL and
b-actin in controls, and pRc/RSV (empty vector) and pRSV-hPit-1-transfected MCF-7 cells for 48 h. The major 31 and 33 kDa
immunoreactive bands corresponding to Pit-1, as well as glycosylated (25 kDa) and nonglycosylated PRL (23 kDa), are indicated by
arrows. (E) Western blots of Pit-1, PRL, and b-actin in control MCF-7 cells, and in cells transfected with 20 nM siRNA negative
control and 20 nM Pit-1 siRNA for 48 h. (***P!0.001 and **P!0.01 versus control cells).
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in Fig. 1A, a clear increase of PRL mRNA
expression in all mammary cell lines was found
after Pit-1 overexpression. Quantitative PCR revealed
a signiﬁcant PRL increase in all cell lines evaluated
after Pit-1 transfection as compared with cells
transfected with the control vector (Fig. 1B). In
addition, MCF-7 cells transfected with pRSV-hPit-1
vector were analyzed by quantitative PCR at 24, 48,
and 72 h (Fig. 1C). The results of these analyses
indicated a signiﬁcant (P!0.001) increase in the
PRL mRNA expression at 48 and 72 h compared
with untransfected MCF-7 cells; however, this was
not the case at 24 h.
Figure 1D shows the western blotting of Pit-1,
PRL, and b-actin (used as loading control) in MCF-7
cells transfected with pRSV-hPit-1 or pRc/RSV (used
as a control). Pit-1 has two major immunoreactive
bands that are readily visible in samples from human
cell lines and human mammary glands. These bands
that arise from two alternative translation–initiation
codons in Pit-1 mRNA have previously been referred
to as the 31 and 33 kDa bands (Voss et al. 1991,
Gil-Puig et al. 2005). PRL also shows two immuno-
reactive bands corresponding to the glycosylated
(25 kDa of molecular weight) and nonglycosylated
(23 kDa) forms (Markoff & Lee 1987, Shinha 1995).
As expected, transfection of MCF-7 cells with pRSV-
hPit-1 construct induced a signiﬁcant increase in Pit-1
protein expression (upper panel). PRL was detectable
in control (untransfected) MCF-7 cells, as well as in
pRc/RSV-transfected cells. Higher PRL expression
was observed at 48 h in pRSV-hPit-1 construct
compared with pRc/RSV-transfected cells. To evalu-
ate whether Pit-1 knockdown induces changes in
PRL, siRNA was used. MCF-7 cells were transfected
with a missense siRNA or Pit-1 siRNA. As shown in
Fig. 1E, transfection of MCF-7 cells with 20 nM
missense siRNA failed to modify Pit-1 or PRL
expression levels compared with the untransfected
control cells. However, knockdown of Pit-1 by
transfection with 20 nM Pit-1 siRNA resulted in
markedly reduced expression of both Pit-1 and PRL.
MCF-7 cells contain only the PRL proximal
pituitary promoter
PRL mRNA transcripts in extrapituitary tissues have
been shown to be different from those of pituitary
origin, thus suggesting several mechanisms of PRL
gene regulation (Fig. 2A). Hence, using RT-PCR,
we evaluated the type of PRL mRNA that was
transcribed in our experimental cell line model.
As shown in Fig. 2B, human pituitary tissue (used
as positive control, lanes 2 and 3), NIH 3T3 cells
(used as negative control, lanes 4 and 5), MCF-7
cells (lanes 6 and 7), and HeLa cells (lanes 8 and 9)
were analyzed by RT-PCR, using speciﬁc primers
for the PRL extrapituitary (primers Ex1a–Ex2) and
pituitary (primers Ex1b–Ex2) transcripts (see
Fig. 2A). While HeLa cells express both pituitary
and extrapituitary PRL mRNA transcripts, the
MCF-7 cells showed only one band of 194 bp
(lane 7), as is observed in the PCR of human
pituitary extract (lane 3; Fig. 2B).
Pit-1 regulates PRL expression in MCF-7 cells by
binding to the PRL proximal promoter
To evaluate the possible effect of Pit-1 on PRL
transcriptional activity, MCF-7 cells were transfected
with either a construct linking 217 bp of the proximal
PRL gene promoter to a luciferase reporter vector
(pGL2B-hPRLK216/C1, Fig. 2C) or the pGL2-basic
vector, and then cotransfected with the pRSV-hPit-1
vector. At 48 h after transfection, cells were harvested
for measurement of luciferase activity. As shown in
Fig. 2D, cotransfection with the pGL2B-hPRLK216/C1
and the pRSV-hPit-1 led to a signiﬁcant increase in
luciferase activity (P!0.001). In order to specify the
location of Pit-1 binding to the PRL promoter, we
carried out a site-directed mutagenesis on two known
Pit-1-binding sites (Peers et al. 1991; Fig. 2C),
and then cotransfected these constructs with the
pRSV-hPit-1 expression vector. As shown in Fig. 2D,
the transcriptional increase obtained using the wild-
type pGL2B-hPRLK216/C1 construct was signiﬁcantly
reduced when the mutated PRL promoter constructs
were cotransfected with the pRSV-hPit-1 vector,
demonstrating that these elements are functional.
To conﬁrm in vivo interaction of Pit-1 with the
hPRL proximal promoter, a ChIP assay was carried
out. As shown in Fig. 2E, the ChIP PCR product
was detected with the Pit-1 antibody and speciﬁc
primers to the proximal PRL promoter in control,
untransfected, and pRSV-hPit-1-transfected MCF-7
cells, suggesting that endogenous Pit-1 speciﬁcally
binds to the regulatory region (K216/C1) of the
PRL promoter.
Effect of overexpression and silencing of Pit-1 on
the proliferation of MCF-7 cells
To evaluate the effect of Pit-1 overexpression on
MCF-7 cell proliferation, these cells were transfected
with pRSV-hPit-1 expression vector for 48 h
along with a puromycin-resistance-encoding vector
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As reported by Gil-Puig et al. (2005), cells transfected
with pRSV-hPit-1 showed an increase in BrdU
uptake with respect to control cells (23.98G1.20 vs
11.64G0.72%, P!0.001; Fig. 3Aa n dB ) .T o
explore the role of endogenous Pit-1 on MCF-7 cell
proliferation, we used the siRNA approach. As shown
in Fig. 3A and B, MCF-7 cells were transfected with
20 nM Pit-1 siRNA (or 20 nM of a missense siRNA,
negative control) along with a puromycin-resistance-
encoding vector (pEPuro), and selected with 1 mg/ml
puromycin. We found that siRNA-mediated Pit-1
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Figure 2 PRL from MCF-7 cell line is identical to PRL of pituitary origin, and it is transcriptionally regulated by Pit-1. (A) Diagram of
human PRL gene and promoter showing the location of the primers used in the RT-PCR assay as well as the proximal pituitary
transcript and the distal extrapituitary transcript. (B) PCR products obtained from human pituitary gland, NIH-3T3, MCF-7, and HeLa
cell lines using primers that ampliﬁed proximal pituitary transcript (194 bp) or distal extrapituitary transcript (275 bp). Lane 1,
molecular weight marker; lanes 2 and 3, PCR product from human pituitary using PRL extrapituitary (negative control) or pituitary
(positive control) primers respectively; lanes 4 and 5, PCR products from NIH-3T3 cells (used as negative control) using PRL
extrapituitary or pituitary primers respectively; lanes 6 and 7, PCR products from MCF-7 cells using PRL extrapituitary or pituitary
primers respectively; lanes 8 and 9, PCR products from HeLa cells using PRL extrapituitary or pituitary primers respectively (positive
control). (C) Diagram of the proximal PRL gene promoter construct (pGL2B-hPRLK216/C1) and the mutated constructs (pGL2B-
hPRLmut1, pGL2B-hPRLmut2, and pGL2B-hPRLmut1C2) showing the location of the Pit-1-binding sites and the mutated bases.
(D) Either the wild proximal pituitary PRL promoter or a mutant PRL promoter fused to the pGL2 basic vector was cotransfected with
the pRSV-hPit-1 expression vector into MCF-7 cells using FuGene reagent, and cells were then cultured for 48 h. Normalized
relative luciferase units (RLU) werecalculatedas the ratioof luciferase activity in cells transfected with the wild or mutated constructs
to the activity in the corresponding control cells. (*P!0.05; ***P!0.001 versus control cells). (E) Soluble chromatin prepared from
control MCF-7 cells, cells transfected with the pRSV-hPit-1 vector, and cells transfected with the control vector (pRc/RSV) were
immunoprecipitated with an anti-Pit-1 antibody or control IgG. The immunoprecipitated DNA was ampliﬁed by PCR using speciﬁc
primers corresponding to the proximal PRL promoter (from K216 to C1, with respect to the start transcription site).
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www.endocrinology-journals.org 79knockdown signiﬁcantly (P!0.001) reduced BrdU
uptake as compared with control siRNA-treated cells
(1.93G0.30 vs 10.49G1.23%).
To explore the effect of PRL administration on cell
proliferation after Pit-1 siRNA knockdown, MCF-7
cells were transfected either with Pit-1 siRNA or
control siRNA and 24 h later treated with 10 nM hPRL.
After 24 h, cells were labeled with BrdU. Results are
shown in Fig. 3A. As previously reported by Brockman
et al. (2002), administration of hPRL to cells induced a
signiﬁcant increase (P!0.001) in cell proliferation
with respect to untreated control cells. However,
exogenous hPRL administration to cells after Pit-1
siRNA transfection signiﬁcantly (P!0.001) reduced
cell proliferation with respect to the cells treated with
hPRL alone. Figure 3B shows a representative panel of
DAPI and BrdU in control, PRL-treated and/or
transfected MCF-7 cells.
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of cells stained with a FITC-conjugated anti-BrdU antibody and counterstained with 4,6-diamine-2-phenylindole (DAPI). Proliferation
rate was calculated as the percentage of BrdU-positive nuclei with respect to DAPI-positive nuclei. Values represent meansGS.D.
from four independent determinations (***P!0.001). (B). Representative set ofﬂuorescence microphotographs from the experiment
described in (A). Original magniﬁcations !20. (C) Western blot of Jak2, Jak2 phosphorylated, and b-actin in control MCF-7 cells
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weretransfected, selected, and BrdUlabeledasin (A). Markedcells (C) alsoreceivedAG-490(30 mM) at24 h. Proliferation rateand
values calculated and carried out as in (A). (E) Representative set ofﬂuorescence microphotographs from the experiment described
in (D). Original magniﬁcations !20.
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Pit-1-increased cell proliferation (i.e. independently or
PRL-mediated), we administrated AG-490, a potent
inhibitor of the Jak2 tyrosine kinase, which is critical
for transmission of PRL-induced proliferative signals
(Brockman et al. 2002). As shown in Fig. 3C (lane 4),
Pit-1 overexpression induced an increase in Jak2
phosphorylation, which was blocked (lane 5) after
AG-490 administration. Thus, AG-490 administration
signiﬁcantly reduced MCF-7 cell proliferation
(4.6G0.4%; P!0.001) compared with control cells
(11.9G1.5%; Fig. 3D). However, cell proliferation
returned to normal values when the cells were treated
with the AG-490 drug together with overexpressed
Pit-1 transcription factor (10.8C0.8%; Fig. 3D).
A panel with representative images of BrdU incorpor-
ation in control and treated and/or transfected MCF-7
cells is shown in Fig. 3E. To analyze more closely
whether the increase in cell proliferation after Pit-1 was
PRL dependent, total cell extracts were taken from
MCF-7 cell controls and from those transfected with
pRc/RSV or pRSV-hPit-1 vector at 12 and 48 h and,
then, subjected to western blotting using speciﬁc
antibodies. Western blots of Pit-1, PRL, cyclin D1
(as indicator of cell proliferation), and b-actin (used as
loading control) are shown in Fig. 4Aa n dC .
Transfection of cells with the pRSV-hPit-1 vector for
12 h induced a signiﬁcant increase in Pit-1 (1.0G0.24),
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Figure 4 Pit-1 leads to a PRL-independent increase in cyclin D1. (A and C) Western blots of Pit-1, PRL, cyclin D1, and b-actin (used
as loading control) were performed on control, pRc/RSV, and pRSV-hPit-1-transfected MCF-7 cells at 12 and 48 h respectively.
(B and D) Relative protein levels in control MCF-7 cells and cells transfected with the pRc/RSV or pRSV-hPit-1 vector after 12 and
48 h respectively were calculated as the ratio of Pit-1, cyclin D1, and PRL with respect to the b-actin protein levels. Values represent
meanGS.D. from densitometric evaluation of three western blots from independent experiments. (E) MCF-7 cells were transfected
with 20 nM missense siRNA or 20 nM PRL siRNA. Forty-eight hours later, PRL protein immunoreactivity was evaluated by western
blot. (F) MCF-7 cells were cotransfected with the pRSV-hPit-1 overexpression vector (2.5 mg) together with PRL siRNA (20 nM), and
48 h later, Pit-1, PRL, cyclin D1, and b-actin (as loading control) were evaluated by western blot.
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with respect to untransfected cells (0.50G0.1 and
0.18G0.09 respectively, P!0.05). At this stage, PRL
protein levels remained unmodiﬁed (0.30G0.19)
compared with untransfected (0.27G0.25) and
pRc/RSV (0.36G0.33) transfected cells (Fig. 4B).
However, 48 h after Pit-1 overexpression, a signiﬁcant
increase in PRL immunoreactive expression levels was
observed (see Fig. 1B), in addition to the increase in
Pit-1 and cyclin D1 protein levels (Fig. 4C and D).
To further explore if Pit-1 could increase cyclin D1
levels independently of PRL, endogenous PRL levels
of MCF-7 cells were knocked down by transfecting
a PRL siRNA (20 nM). Simultaneously, the pRSV-
hPit-1 overexpression vector was also transfected.
Figure 4E shows the effect at 48 h of PRL siRNA
transfection on PRL immunoreactive protein levels in
MCF-7 cells. Also at 48 h, Fig. 4F shows a visible
increase in cyclin D1 and Pit-1, but not PRL, after
Pit-1 overexpression and PRL siRNA cotransfection.
These data suggest a PRL-independent effect of Pit-1
on cyclin D1.
Pit-1 and PRL protein expression in human
breast tumors
TofurtherevaluateapossiblerelationshipbetweenPit-1
and PRL expression in human breast tissue, both Pit-1
and PRL proteins were analyzed by immunohisto-
chemistryin94invasiveductalcarcinomasofthebreast.
Figure 5 shows representative examples of tumors with
immunostaining for each protein evaluated. Pit-1
protein expression was detected mainly in nuclei of
tumor or control epithelial cells, whereas PRL immuno-
reactivity showed cytoplasmic staining in both cases
(Fig. 5A and B). A total of 81 tumors (86.1%) showed
positive immunostaining for Pit-1, whereas 73 tumors
(77.6%) showed positive immunostaining for PRL.
Nevertheless, as can be seen in Table 1, there was
variability in staining intensity for these factors. Our
results also show a high concordance in the expression
of Pit-1 and PRL. Thus, a total of 84 tumors (89.3%)
showed concordance in the crude expressions of Pit-1
andPRL(P!0.0001).Signiﬁcantconcordancewasalso
found between these two proteins with respect to grades
of immunostaining intensity (P!0.0001; Table 1).
B Human pitutary (positive control)
PRL Pit-1
Human breast invasive ductal carcinomas A
Negative
PRL
Pit-1
Positive (1+) Positive (2+) Positive (3+)
Figure 5 Immunohistochemical detection of Pit-1 and PRL expression in human breast tissue. (A) Representative set of negative
and positive (1C,2 C, and 3C) PRL and Pit-1 immunodetection in human breast invasive ductal carcinomas. (B) Human pituitary
gland was used as positive control to detect PRL and Pit-1 immunopositivity. Original magniﬁcation !20.
Table 1 Relationships between Pit-1 and prolactin expression in
94 human breast invasive ductal carcinomas
Prolactin
Pit-1 0 1C 2C 3C
Total
cases
01 2 0 1 0 1 3
1C 42 7 2 0 3 3
2C 51 42 0 1 4 0
3C 052 1 8
Total cases 21 46 25 2 94
Intensity of staining: 0, not staining; 1, weak; 2, moderate;
3, intense. c
2Z69.36; P!0.0001.
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To explore the possible regulation of PRL by Pit-1 in
human breast, several tumoral mammary cell lines
were transfected with the Pit-1 expression vector. Our
results demonstrate a signiﬁcant increase in PRL
mRNA 48 and 72 h after transfection with the pRSV-
hPit-1 expression vector. In addition, a signiﬁcant
increase in PRL protein expression was observed in the
MCF-7 cell line after Pit-1 overexpression. Conver-
sely, a signiﬁcant decrease in PRL protein expression
was observed after Pit-1 knockdown. Taken together,
these data seem to suggest that either endogenous or
exogenous Pit-1 regulates PRL expression, at least in
some mammary cell lines. Moreover, the luciferase
reporter and ChIP assays reveal that this regulation
is produced by Pit-1 binding to a proximal PRL
promoter region.
At the pituitary level, it is well known that Pit-1
binds to the proximal PRL promoter and induces PRL
expression. However, some extrapituitary tissues and
cell lines, such as prostate cancer cells and the human
breast adenocarcinoma cells, SK-BR-3, do not express
Pit-1, yet PRL transcripts corresponding to the
proximal promoter are present (Shaw-Bruha et al.
1997, Manfroid et al. 2005, Dagvadorj et al. 2007).
This seems to support that Pit-1-independent PRL
regulation in nonpituitary tissues can occur. For
example, in a subclone of the SKUT-1B uterine
sarcoma cell line, Pit-1 transfection does not modify
endogenous PRL levels (Gellersen et al.1 9 9 5 ).
However, in SK-BR-3 cells that contain PRL but not
Pit-1, overexpression of Pit-1 induces the activation of
transfected constructs containing the proximal pitu-
itary PRL promoter (Manfroid et al. 2005) and the
induction of PRL mRNA, as observed in our study.
Pit-1 induction has also been demonstrated to lead to
PRL or GH expression in other extrapituitary tissues.
For instance, adenoviral delivery of Pit-1 in mouse
liver induces the transient differentiation of adult
hepatic stem cells into PRL-producing cells (Lee
et al. 2005), and transfection of the corticotropic
AtT-20 and the gonadotropic aT3-1 cell lines with
the Pit-1 overexpression vector induces GH gene
activation (Kurotani et al. 2002).
It has been demonstrated that PRL transcriptionally
increases the levels of cyclin D1 that is a key factor in
cell cycle. This further indicates that PRL directly
induces cell proliferation (Brockman et al. 2002). In
the present study, we also found a signiﬁcant increase
in BrdU uptake after PRL administration. However,
when AG-490 was administered to block the Jak2
pathway and, thus, the possible effect of exogenous or
Pit-1-induced endogenous PRL, overexpression of
Pit-1 to the MCF-7 cells restored cell proliferation to
the basal levels, suggesting a PRL-independent effect
of Pit-1 on cell cycle. In fact, Pit-1 led to an increase in
cyclin D1 expression levels before the increase in PRL
levels was observed, and knockdown of endogenous
PRL together with overexpression of Pit-1 clearly
raised cyclin D1 protein levels. These data seem to
suggest that Pit-1 increases cell proliferation indepen-
dently of PRL probably by inducing cyclin D1 levels.
With respect to this, it has been previously demon-
strated that Pit-1 leads to a signiﬁcant increase in cell
proliferation in both pituitary (Castrillo et al. 1991)
and extrapituitary cell lines (Gaiddon et al. 1999,
Gil-Puig et al. 2005).
To study the relationships between Pit-1 and PRL in
human breast cancer, we also evaluated the Pit-1 and
PRL expression in 94 invasive ductal carcinomas. Our
results indicate a signiﬁcant correlation in the
expression of both proteins. It has previously been
demonstrated that Pit-1 is expressed in both normal
and tumoral human breast, with Pit-1 mRNA levels
being higher in tumors. This suggests that depending
on its level, the expression of Pit-1 may be involved
in normal mammary development, breast disorders,
or both (Gil-Puig et al.2 0 0 5 ). The role of PRL
in inducing mammary tumorogenesis has been
thoroughly discussed (Vonderhaar 1999, Wennbo &
To ¨rnell 2000, Ben-Jonathan et al. 2002, Clevenger
et al. 2003). However, few studies have evaluated
PRL expression by immunohistochemistry in series
of human mammary tumors (Bhatavdekar et al.
2000a,b). These authors have shown that PRL
immunoreactivity was present in 78% (87 out of 111)
and 82% (76 out of 93) of tumors, similar to our own
ﬁnding (77%, 73/94), and that increased PRL positivity
was signiﬁcantly associated with increased tumor size,
higher stage, nodal involvement, and worse overall
survival in univariate analyses, although the associ-
ation was attenuated after adjustment for stage
(Bhatavdekar et al. 2000a). No data about determina-
tion of Pit-1 expression by immunohistochemistry in
human breast tumor series is currently available. At
least with respect to invasive ductal carcinomas of the
breast, the statistically signiﬁcant correlation between
PRL and Pit-1 expression observed in the present study
seems to suggest that Pit-1 could be involved in the
pathogenesis of breast tumors either as a regulator of
PRL or independently.
In summary, the present study demonstrates that
Pit-1 regulates PRL mRNA and protein expression in
human mammary cell lines, that Pit-1 increases cyclin
D1 independently of PRL, and that a signiﬁcant
Endocrine-Related Cancer (2010) 17 73–85
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human breast invasive ductal carcinomas. Taken
together, our data seem to suggest that Pit-1 through
PRL and/or independently of PRL could be related to
mammary cell transformation.
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